Resonant is a disruptive neurodegenerative disease biotechnology company that develops groundbreaking blood tests that accurately detect and monitor DNA from dying neurons. This DNA serves as biomarkers of neurodegeneration in diseases like Alzheimer’s and may be predictive of neurodegenerative diagnoses before clinical symptoms appear. Resonant is currently conducting a large-scale clinical validation study of its tests for Alzheimer’s, Parkinson’s, and ALS with plans to develop tests for other neurodegenerative conditions such as traumatic brain injury and multiple sclerosis. Visit Our Website

Powered by pioneering technology from leading experts in genetics, epigenetics, and bioinformatics, we have developed NESSI-Seq—a groundbreaking biomarker discovery platform. NESSI-Seq overcomes many current limitations in next-generation sequencing (NGS) and is positioned to revolutionize the field, enabling entry into untapped, high-impact markets. Visit Our Website

Pathogen is a dynamic biotechnology company revolutionizing the detection and monitoring of biomarkers of Lyme and other infectious diseases. With proprietary targeted sequencing technology for identifying and quantifying pathogen-derived DNA directly from blood samples. This technology allows for the early detection of infection biomarkers elusive to conventional methods. With its precise and adaptable approach, Pathogen is well-positioned to develop diagnostic tests for a wide array of infectious diseases.

eXXperts is a pioneering biotechnology company advancing women's health thorugh targeted DNA sequencing technologies. Specializing in the detection of biomarkers for conditions disproportionately affecting women, such as endometriosis and gynecological cancers, eXXperts also develops forensic applications to distinguish menstrual from peripheral blood to aid investigations of crimes against women.

NanoHyb develops novel next-generation sequencing (NGS) technologies that address current limitations in research and clinical services for complex disease. Leveraging the Nanopore platform, Nanohyb has developed targeted sequencing applications that have laid the groundwork for NESSI-Seq. These applications enable researchers to directly sequence and detect epigenetic modifications at thousands of DNA regions for single molecule analyses that are highly accurate and reflective of biology.